Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Individualized Cancer Prevention and Management
share announcement

Individualized Cancer Prevention and Management

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (15 December 2023) | Viewed by 2871

Special Issue Editors

Dr. Yazhou He

E-Mail Website
Guest Editor
Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
Interests: genetic and molecular epidemiology on cancer with a particular interest in colorectal cancer
Dr. Xin Wang

E-Mail Website
Guest Editor
Department of Epidemiology and Medical Statistics, West China School of Public Health, Sichuan University, Chengdu, China
Interests: epidemiology and predictive modeling
Dr. Xue Li

E-Mail Website
Guest Editor
Usher Institute, University of Edinburgh, Edinburgh, UK
Interests: phenome-wide investigations for cancer outcomes
Prof. Dr. Chuan Xu

E-Mail Website
Guest Editor
Department of Cancer Biology, School of Medicine, Wake Forest University, Winston Salem, NC 27101, USA
Interests: molecular biology and immunology in cancer research

Special Issue Information

Dear Colleagues,

Cancer remains the second leading cause of death worldwide. From normal epithelium to invasive and eventually metastatic tumors, carcinogenesis is accompanied by the stepwise accumulation of both germline and somatic genetic alterations. Recent research has demonstrated that cancer is a group of heterogeneous tumors characterized by distinct molecular patterns. In relation to germline variations, advances in genome-wide association studies (GWAS) based on a large collaborative consortium and biobank are illuminating the genetic architecture which included thousands of independent genetic risk loci. As for somatic alterations, the increasingly applied high-throughput sequencing techniques along with comprehensive efforts such as The Cancer Genome Atlas (TCGA) have allowed for improved identification and visualization of pathogenic mutations for various cancers. More importantly, these identified molecular markers, along with clinic-omics data, have shown great potential in assisting individualized cancer risk prediction and, subsequently, in advising the tailored treatment regimen. In addition, the integrative analysis of transcriptomes, proteiomes, metabolomes and clinical phenomes has enabled more a comprehensive understanding of biological mechanisms underlying carcinogenesis and cancer progression.  Herein, we initiate this Special Issue which will feature reviews and original investigations on individualized cancer prevention and patient management.   

Dr. Yazhou He
Dr. Xin Wang
Dr. Xue Li
Prof. Dr. Chuan Xu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • genomics
  • molecular genetics
  • personalized management
  • precision medicine
  • multi-omics

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 499 KiB  
Article
CDKN2A Gene Mutations: Implications for Hereditary Cancer Syndromes
by Anastasiia Danishevich, Airat Bilyalov, Sergey Nikolaev, Nodirbec Khalikov, Daria Isaeva, Yuliya Levina, Maria Makarova, Marina Nemtsova, Denis Chernevskiy, Olesya Sagaydak, Elena Baranova, Maria Vorontsova, Mariya Byakhova, Anna Semenova, Vsevolod Galkin, Igor Khatkov, Saida Gadzhieva and Natalia Bodunova
Biomedicines 2023, 11(12), 3343; https://doi.org/10.3390/biomedicines11123343 - 18 Dec 2023
Cited by 2 | Viewed by 1394
Abstract
Malignant neoplasms, including pancreatic cancer and melanoma, are major global health challenges. This study investigates melanoma pancreatic syndrome, a rare hereditary tumor syndrome associated with CDKN2A gene mutations. CDKN2A mutations contribute to a lifetime risk of melanoma ranging from 28% to 67%. This [...] Read more.
Malignant neoplasms, including pancreatic cancer and melanoma, are major global health challenges. This study investigates melanoma pancreatic syndrome, a rare hereditary tumor syndrome associated with CDKN2A gene mutations. CDKN2A mutations contribute to a lifetime risk of melanoma ranging from 28% to 67%. This study reports the clinical features of six individuals with CDKN2A mutations and identifies recurrent alterations such as c.307_308del, c.159G>C and c.71G>C. It highlights the need for CDKN2A mutation testing in suspected cases of familial atypical multiple mole melanoma. Clinically significant variants show associations with melanoma and pancreatic cancer. The challenges of treating individuals with CDKN2A mutations are discussed, and the lack of specific targeted therapies is highlighted. Preclinical studies suggest a potential benefit of CDK4/6 inhibitors, although clinical trials show mixed results. This study underscores the importance of continued research into improved diagnostic and therapeutic strategies to address the complexities of hereditary cancer syndromes. Full article
(This article belongs to the Special Issue Individualized Cancer Prevention and Management)
►▼ Show Figures

Figure 1

Review

Jump to: Research

14 pages, 909 KiB  
Review
Application of Inflatable Video-Assisted Mediastinoscopic Transhiatal Esophagectomy in Individualized Treatment of Esophageal Cancer
by Shangqi Song, Cheng Shen, Yang Hu, Yazhou He, Yong Yuan and Yuyang Xu
Biomedicines 2023, 11(10), 2750; https://doi.org/10.3390/biomedicines11102750 - 11 Oct 2023
Viewed by 912
Abstract
Surgery is a crucial treatment option for patients with resectable esophageal cancer. The emergence of minimally invasive esophageal techniques has led to the popularity of video-assisted thoracoscopic esophagectomy, which has proven to be more advantageous than traditional thoracotomy. However, some patients with esophageal [...] Read more.
Surgery is a crucial treatment option for patients with resectable esophageal cancer. The emergence of minimally invasive esophageal techniques has led to the popularity of video-assisted thoracoscopic esophagectomy, which has proven to be more advantageous than traditional thoracotomy. However, some patients with esophageal cancer may not benefit from this procedure. Individualized treatment plans may be necessary for patients with varying conditions and tolerances to anesthesia, making conventional surgical methods unsuitable. Inflatable video-assisted mediastinoscopic transhiatal esophagectomy (IVMTE) has emerged as a promising treatment option for esophageal cancer because it does not require one-lung ventilation, reduces postoperative complications, and expands surgical indications. This technique also provides surgical opportunities for patients with impaired pulmonary function or thoracic lesions. It is crucial to have a comprehensive understanding of the advancements and limitations of IVMTE to tailor treatment plans and improve outcomes in patients with esophageal cancer. Understanding the advantages and limitations of this surgical method will help specific patients with esophageal cancer. We conducted a thorough review of the relevant literature to examine the importance of IVMTE for individualized treatment of this disease. Full article
(This article belongs to the Special Issue Individualized Cancer Prevention and Management)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop